A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer

Launched by THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY · Nov 18, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new imaging technique called 68Ga-MY6349 PET/CT to improve the way we diagnose and monitor prostate cancer. The goal is to create a better imaging tool that can identify prostate cancer and other aggressive tumors more accurately than existing methods. By targeting a specific protein found in many cancers, this study aims to provide clearer pictures of tumors, which could lead to earlier diagnoses and more effective treatment plans.

To participate in this study, you must be a male diagnosed with prostate cancer, either for the first time or after treatment has not been successful. Participants should expect to undergo imaging tests and will need to sign a consent form to take part in the study. However, there are some reasons you might not be eligible, such as having difficulty with needles or certain medical conditions that could affect your ability to complete the imaging. If you're interested and meet the criteria, this trial could help advance prostate cancer care.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with initial diagnosis of prostate cancer, or patients with biochemical recurrence after radical prostatectomy or radical radiotherapy.
• • 2. Estimated survival time \>3 months, as determined by a physician.
• • 3. Willing to sign the informed consent form voluntarily and able to comply with the study protocol.
• Exclusion Criteria:
• • 1. Individuals unable to tolerate intravenous administration (e.g., history of needle or blood phobia).
• • 2. Patients deemed unsuitable by researchers or unable to complete PET or other imaging examinations due to specific conditions, such as claustrophobia or radiophobia.
• • 3. Individuals with occupational exposure to radiation.
• • 4. Patients with severe diseases affecting the heart, kidneys, lungs, vascular, neurological, or mental systems, immune deficiency disorders, or hepatitis/cirrhosis.
• • 5. Other conditions that researchers deem unsuitable for participation in the study.